Page 98 - GTM-3-3

Global Translational Medicine SLE patient underwent PD

cytometry. Nat Biotechnol. 2019;37(7):773-782. Gastroenterol Hepatol. 2024;22(3):499-512.e6.
doi: 10.1038/s41587-019-0114-2 doi: 10.1016/j.cgh.2023.07.027
13. Newman AM, Liu CL, Green MR, et al. Robust enumeration 18. Schalck A, Sakellariou-Thompson D, Forget MA,
of cell subsets from tissue expression profiles. Nat Methods. et al. Single-Cell sequencing reveals trajectory of tumor-
2015;12(5):453-457. infiltrating lymphocyte states in pancreatic cancer. Cancer
doi: 10.1038/nmeth.3337 Discov. 2022;12(10):2330-2349.
14. Wei R, Zhu WW, Yu GY, et al. S100 calcium-binding protein doi: 10.1158/2159-8290.Cd-21-1248
A9 from tumor-associated macrophage enhances cancer 19. Weigelin B, Friedl P. T cell-mediated additive
stem cell-like properties of hepatocellular carcinoma. Int J cytotoxicity - Death by multiple bullets. Trends Cancer.
Cancer. 2021;148(5):1233-1244. 2022;8(12):980-987.
doi: 10.1002/ijc.33371 doi: 10.1016/j.trecan.2022.07.007
15. Serenari M, Ercolani G, Cucchetti A, et al. The impact of 20. Voskoboinik I, Whisstock J, Trapani JA. Perforin and
extent of pancreatic and venous resection on survival for granzymes: Function, dysfunction and human pathology.
patients with pancreatic cancer. Hepatobiliary Pancreat Dis Nat Rev Immunol. 2015;15(6):388-400.
Int. 2019;18(4):389-394.
doi: 10.1038/nri3839
doi: 10.1016/j.hbpd.2019.06.004
21. Cao Y, He H, Li R, et al. Latency-associated peptide identifies
16. Fromentin M, Mullaert J, Gille B, et al. Extended antibiotic immunoevasive subtype gastric cancer with poor prognosis
prophylaxis after pancreatoduodenectomy reduces and inferior chemotherapeutic responsiveness. Ann Surg.
postoperative abdominal infection in high-risk patients: 2022;275(1):e163-e173.
Results from a retrospective cohort study. Surgery.
2022;172(1):205-211. doi: 10.1097/sla.0000000000003833
doi: 10.1016/j.surg.2021.12.028 22. Sun H, Huang Q, Huang M, et al. Human CD96 correlates
to natural killer cell exhaustion and predicts the prognosis
17. Gupta A, Peyrin-Biroulet L, Ananthakrishnan AN. Risk
of cancer recurrence in patients with immune-mediated of human hepatocellular carcinoma. Hepatology.
diseases with use of immunosuppressive therapies: 2019;70(1):168-183.
An updated systematic review and meta-analysis. Clin doi: 10.1002/hep.30347

Volume 3 Issue 3 (2024) 7 doi: 10.36922/gtm.2893